imatinib

imatinib is a tyrosine kinase inhibitor medication used primarily in the treatment of certain cancers. It revolutionized the management of chronic myelogenous leukemia and gastrointestinal stromal tumor by targeting specific molecular abnormalities. Developed by Novartis, it is considered a paradigm of targeted therapy and a landmark achievement in oncology.

Medical uses

imatinib is indicated for the treatment of adult and pediatric patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, accelerated phase, or blast crisis. It is also approved for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia and for adult patients with KIT-positive gastrointestinal stromal tumor following surgical resection or in metastatic disease. Additional uses include treating patients with myelodysplastic syndrome or myeloproliferative disease associated with platelet-derived growth factor receptor gene rearrangements, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. Its efficacy is monitored through polymerase chain reaction testing for BCR-ABL1 transcript levels.

Adverse effects

Common adverse effects include edema, nausea, diarrhea, muscle cramps, rash, and fatigue. More serious potential effects encompass neutropenia, thrombocytopenia, hepatotoxicity, and congestive heart failure. Severe fluid retention can manifest as pleural effusion, pericardial effusion, pulmonary edema, and ascites. Cases of tumor lysis syndrome have been reported, primarily in patients with high tumor burden. The Food and Drug Administration and European Medicines Agency maintain safety profiles through post-marketing surveillance.

Pharmacology

imatinib functions as a selective inhibitor of several tyrosine kinase enzymes, including the BCR-ABL1 fusion protein, KIT receptor, and platelet-derived growth factor receptor. It competitively binds to the adenosine triphosphate-binding site of the target kinase, stabilizing it in an inactive conformation and preventing phosphorylation of substrates involved in cell proliferation and apoptosis signaling. The drug is metabolized primarily in the liver by the cytochrome P450 system, specifically the CYP3A4 isoenzyme, and its main active metabolite is the N-desmethyl derivative. Pharmacokinetics can be affected by co-administration with CYP3A4 inducers like rifampicin or inhibitors like ketoconazole.

History

The development of imatinib originated from research at Ciba-Geigy, which later merged with Sandoz to form Novartis. Key scientists involved in its discovery include Nicholas Lydon and Brian Druker, with critical contributions from Charles Sawyers and Michele Baccarani. Its clinical development was accelerated by unprecedented results in Phase I trials for chronic myelogenous leukemia, leading to Food and Drug Administration approval in 2001 under the Orphan Drug Act. The drug's success validated the concept of rational drug design against a specific molecular target identified through research on the Philadelphia chromosome by Janet Rowley and others.

Society and culture

Marketed under the trade names Gleevec in the United States and Glivec elsewhere, imatinib has been the subject of significant discussion regarding drug pricing and access to medicines. Novartis faced legal challenges in India over its patent application, a case decided by the Supreme Court of India. The drug's impact is frequently cited in debates about the value of precision medicine and the sustainability of healthcare systems. Its story has been featured in media, including the documentary film Fire with Fire, and it is listed on the World Health Organization Model List of Essential Medicines.

Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors Category:World Health Organization essential medicines